Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Negoro S, Fukuoka M, Masuda N, et al.: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991, 83:1164–1168.
2. Ohe Y, Sasaki Y, Shinkai T, et al.: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992, 84:972–974.
3. Rothenberg ML, Kuhn JG, Burris III, HA et al.: Phase I and Pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993, 11:2194–2204.
4. Rowinsky EK, Grochow LB, Ettinger DS, et al.: Phase I and pharmacological study of the novel topoisomerase inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety minute infusion every three weeks. Cancer Res 1994, 54:427–436.
5. Abigerges D, Carbot GG, Armand JP, et al.: Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every three weeks in cancer patients. J Clin Oncol 1995, 13:210–221.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献